Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Lovastatin 1 endocrinologydiseasesdrugs
pravastatin 2 endocrinologydiseasesdrugs
simvastatin 2 endocrinologydiseasesdrugs
type 1 diabetes mellitus 2 endocrinologydiseases
type 2 diabetes mellitus 5 endocrinologydiseases
atorvastatin 2 endocrinologydiseasesdrugs
cerivastatin 2 endocrinologydiseasesdrugs
diabetes mellitus 7 endocrinologydiseases
rosuvastatin 2 endocrinologydiseasesdrugs

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Lovastatin 10043 10 mg/d192051533.331.022.820.818E. Hommel 1992 [[13]]DenmarkSimvastatin, 10–20 mg/d1296789413527273Lam 1995 [[14]]China Lovastatin , 30 mg/d161812.516.758.953.9——24S.Nielsen 1993 [[15]]DenmarkSimvastatin 10–20 mg/d81000656510.210.99Zhang
atorvastatin 4300 Medical Subject Headings (MeSH) and text words were used: Hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin , simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, cerivastatin, mevastatin, pitavastatin,
atorvastatin 8706 Eight different statins involved in this study, including simvastatin [[12], [13], [15], [17], [22]], atorvastatin [[9], [11], [20], [21]], pitavastatin [[18]], lovastatin [[14]], cerivastatin [[19]], rosuvastatin [[10]]
cerivastatin 4379 reductase inhibitors, atorvastatin, simvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, cerivastatin , mevastatin, pitavastatin, statin, kidney, renal, diabetic nephropathy, randomized controlled trial
cerivastatin 8784 [13], [15], [17], [22]], atorvastatin [[9], [11], [20], [21]], pitavastatin [[18]], lovastatin [[14]], cerivastatin [[19]], rosuvastatin [[10]] and pravastatin [[16]]. The study period ranged from approximately 3 months
pravastatin 4341 were used: Hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin, simvastatin, rosuvastatin, pravastatin , lovastatin, fluvastatin, cerivastatin, mevastatin, pitavastatin, statin, kidney, renal, diabetic nephropathy,
pravastatin 8829 [11], [20], [21]], pitavastatin [[18]], lovastatin [[14]], cerivastatin [[19]], rosuvastatin [[10]] and pravastatin [[16]]. The study period ranged from approximately 3 months to 2 years. ACEI or ARB were used in studies,
rosuvastatin 4327 and text words were used: Hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin, simvastatin, rosuvastatin , pravastatin, lovastatin, fluvastatin, cerivastatin, mevastatin, pitavastatin, statin, kidney, renal,
rosuvastatin 8805 atorvastatin [[9], [11], [20], [21]], pitavastatin [[18]], lovastatin [[14]], cerivastatin [[19]], rosuvastatin [[10]] and pravastatin [[16]]. The study period ranged from approximately 3 months to 2 years. ACEI
simvastatin 4314 Headings (MeSH) and text words were used: Hydroxymethylglutaryl-CoA reductase inhibitors, atorvastatin, simvastatin , rosuvastatin, pravastatin, lovastatin, fluvastatin, cerivastatin, mevastatin, pitavastatin, statin,
simvastatin 8662 of eGFR, 5 of UAER, 4 of Scr and 2 of BUN. Eight different statins involved in this study, including simvastatin [[12], [13], [15], [17], [22]], atorvastatin [[9], [11], [20], [21]], pitavastatin [[18]], lovastatin
Select Disease Character Offset Disease Term Instance
diabetes mellitus 1239 −0.12, P = 0.03), respectively. The reduction of albuminuria was greater in patients of type 2 diabetes mellitus with diabetic nephropathy [standardized mean difference (SMD), −0.56; 95 % CI, −0.80 to −0.32,
diabetes mellitus 4843 statins versus control (placebo or usual care); (2) Diabetic nephropathy patients with type 1 and type 2 diabetes mellitus at least 18 years old without pregnancy; (3) Patients with diabetic nephropathy in experimental group
diabetes mellitus 8498 most commonly diabetic nephropathy included in this meta-analysis was diabetic nephropathy with type 2 diabetes mellitus . Ten studies provided data of albuminuria, 5 of eGFR, 5 of UAER, 4 of Scr and 2 of BUN. Eight different
diabetes mellitus 10681 [[22]]ChinaSimvastatin, 20 mg/d3231100100504915146USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus , T1DM type 1 diabetes mellitus, —:not reportTable 2Characteristics of the 14 randomized controlled
diabetes mellitus 10712 20 mg/d3231100100504915146USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus , —:not reportTable 2Characteristics of the 14 randomized controlled trials Included in the meta-analysisStudy
diabetes mellitus 18308 test, pz<0.05 indicate significant association, eGFR estimated Glomerular Filtration Rate, T1DM type 1 diabetes mellitus , T2DM type 2 diabetes mellitus, ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II -receptor
diabetes mellitus 18339 association, eGFR estimated Glomerular Filtration Rate, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus , ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II -receptor blockers, UAER urinary
type 1 diabetes mellitus 10705 20 mg/d3231100100504915146USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus, T1DM type 1 diabetes mellitus , —:not reportTable 2Characteristics of the 14 randomized controlled trials Included in the meta-analysisStudy
type 1 diabetes mellitus 18301 of Q test, pz<0.05 indicate significant association, eGFR estimated Glomerular Filtration Rate, T1DM type 1 diabetes mellitus , T2DM type 2 diabetes mellitus, ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II -receptor
type 2 diabetes mellitus 1232 −3.23 to −0.12, P = 0.03), respectively. The reduction of albuminuria was greater in patients of type 2 diabetes mellitus with diabetic nephropathy [standardized mean difference (SMD), −0.56; 95 % CI, −0.80 to −0.32,
type 2 diabetes mellitus 4836 of statins versus control (placebo or usual care); (2) Diabetic nephropathy patients with type 1 and type 2 diabetes mellitus at least 18 years old without pregnancy; (3) Patients with diabetic nephropathy in experimental group
type 2 diabetes mellitus 8491 The most commonly diabetic nephropathy included in this meta-analysis was diabetic nephropathy with type 2 diabetes mellitus . Ten studies provided data of albuminuria, 5 of eGFR, 5 of UAER, 4 of Scr and 2 of BUN. Eight different
type 2 diabetes mellitus 10674 [[22]]ChinaSimvastatin, 20 mg/d3231100100504915146USA the United States of America, UK United Kingdom, T2DM type 2 diabetes mellitus , T1DM type 1 diabetes mellitus, —:not reportTable 2Characteristics of the 14 randomized controlled
type 2 diabetes mellitus 18332 significant association, eGFR estimated Glomerular Filtration Rate, T1DM type 1 diabetes mellitus, T2DM type 2 diabetes mellitus , ACEI angiotensin-converting enzyme inhibitors, ARB Angiotensin II -receptor blockers, UAER urinary

You must be authorized to submit a review.